ENZYMES IN SIGNAL TRANSDUCTION PATHWAYS

Table of contents :


  • (non-receptor) protein serine / threonine kinases
  • (non-receptor) protein tyrosine kinases (PTK)
  • protein threonine / tyrosine kinases
  • protein histidine kinases
  • lipid kinases
  • lipid phosphatases
  • protein serine / threonine phosphatase
  • protein tyrosine phosphatase (PTP)
  • dual specificity protein serine / tyrosine phosphatase
  • protein threonine / tyrosine phosphatase
  • caspases
  • (non-receptor) guanlyate cyclases (GC)
  • adenylate cyclases (AC)
  • phosphodiesterases (PDE)
  • nucleotide metabolism
  • DNA topoisomerases
  • histone deacetylase (HD / HDAC)
  • histone acetyltransferase (HAT)
  • ATPases
  • phospholipases
  • ANRP
  • AAP
  • Ras-like superfamily
  • GNRP / GEF / GDS
  • GAP
  • GEF & GAP
  • GDI
  • eicosanoid metabolism
  • neurotransmitter anabolism
  • neurotransmitter catabolism
  • Bcl-2 family
  • cytochromes
  • ATP-binding cassette (ABC) proteins
  • matrix metalloproteinases (MMPs)


  •  
    Enzyme family
    enzyme name
    substrate(s)
    activator(s)
    inhibitor(s)
    UDP-glucose ceramide glucosyltransferase (UGCG) / ceramide glucosyltransferase / glucosylceramide synthase 
    (GCS)
    UDP-glucose + ceramide => glucosylceramide N-butyl-deoxynojirimycin (NB-DNJ) / miglustat / OGT 918 (Vevesca®, Zavesca® in Europe)
    OGT2378
    ceramide kinase (CERK)ref
    mammalian target of rapamycin (mTOR)
  • 6-dimethylaminopurine 
  • sirolimus / rapamycin (Rapamune®) complexed to FKBP1A / FKBP12 
  • everolimus / SDZ RAD / 40-O-(2-hydroxyethyl)-rapamycin (Certican®)
  • CCI-779
  • AP23573
  • IMP dehydrogenase (IMPDH) 2, a de novo guanine (Gua) ribo- and 2'-deoxyribonucleotides synthesis enzyme expressed in T- and B-lymphocytes and up-regulated upon cell activation less potent on IMPDH 1, expressed in most cell types. 
     
  • mycophenolate mofetil (MFF) / RS-61443 (Cell-cept®; Myfortic® is the enteric-coated formulation designed to protect the upper G-I tract) is the 2-morpholinoethyl ester prodrug of mycophenolic acid (MPA)


  • Catabolyzed to the inactive mycophenolic acid glucuronide (MPAG)
  • mizoribine (MZB)
  • VX-497
  • dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo pathway of pyrimidine synthesis
  • leflunomide (Arava®) => A77 1726 is noncompetitive versus ubiquinone 
  • polyporic acid
  • brequinar / DUP-785 is a competitive inhibitor versus ubiquinone
    • 2-phenyl 5-quinolinecarboxylic acid (PQC), the core moiety of brequinar, also shows competitive inhibition versus ubiquinone
  • HR325
  • KF20444 
  • barbituric acid (a competitive inhibitor versus DHO)
  • purine nucleoside phosphorylase (PNP) forodesine
    betaine-homocysteine-S-methyltransferase (BHMT) S-(d-carboxybutyl)-DL-homocysteine (CBHcy)ref
    protein serine / threonine kinases Raf1 BAY 43-9006 / sorafenib (Nexavar®) (also inhibits RTKs FLT-3, VEGFR2 and c-KIT)
    GSK-3b 6-dimethylaminopurine 
    6-bromoindirubin-3'-oxime (BIO) 
    Li+
    CDK1 & CDK2 6-dimethylaminopurine 
    flavopiridol 
    UCN-01 / 7-hydroxystaurosporine
    roscovitine 
    CDK9 6-dimethylaminopurine 
    flavopiridol
    p70S6K 6-dimethylaminopurine
    MAPKKKs 6-dimethylaminopurine
    p38 / MAPK1 / ERK2 6-dimethylaminopurine ; 
    SB202190 ; 
    SB203580 ; 
    SB281832 ; 
    PD169316 ; 
    RWJ-67657 ; 
    BiRB0797 ; 
    Ro320-1195 
    VX-745
    SCIO-469
    p44 / MAPK3 / ERK1 6-dimethylaminopurine 
    U0126
    RhoA kinase (ROCK1) 6-dimethylaminopurine 
    Y-27632 [(R)-(+)-trans-N-(4-pyridyl)-4- (1-aminoethyl)cyclohexanecarboxamide]
    PKA : C2R
    • catalytic subunit (C) : except that for mCb3, it is miristoylated but it doesn't anchor it on the cytoplasmic side; they can phosphorylate RII subunits.
      • Ca1 (it can undergo autophosphorylation)
      • Ca2 (inactive)
      • Ca-s
      • bCb1 (it can undergo autophosphorylation)
      • bCb2
      • mCb1
      • mCb2
      • mCb3
      • Cg (it doesn't bind PKI; it can undergo autophosphorylation)
      • PrkX1
    • regulatory subunit
    Sp-8-Br-cAMPS ; 
    dibutiryl-cAMP (dbcAMP) 
    H8 (N-(2- methylaminoethyl) -5-isochinoline sulfonamide. A compound derived from calmodulin antagonists that does no longer possess calmodulin -inhibitory activity.) 
    H89 
    6-dimethylaminopurine
    PKB 6-dimethylaminopurine
    IL-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate
    perifosine [octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate]
    PKC (PS-dependent) 
    • DAG- and Ca2+-dependent or conventional (cPKC)
    • DAG-dependent and Ca2+-independent or novel (nPKC)
    • DAG- and Ca2+-independent, PI-3,4,5-P3-dependent or atypical (aPKC)
    • PKCm / PKD
    • PRK / PKN 1, 2 and 3
    phorbol esters
    bryostatins
    6-dimethylaminopurine 
    calphostin C
    staurosporine
    UCN-01 / 7-hydroxystaurosporine 
    ruboxistaurin mesylate (PKCb-specific)
    Go6976 
    K-252a 
    H7 
    GF 109203X 
    rottlerin
    DNA-PK 6-dimethylaminopurine
    CaMK 6-dimethylaminopurine
    (non-receptor) protein tyrosine kinases (PTK) Janus family (so named as they also have an inactive Ser/Thr kinase domain)  SU5146
    CP-690,550
    Src family (in some RCTKs the SH4 domain is also palmitoylated)  PP2, middle t antigen from SV40


    CGP57148, 
    imatinib mesylate / STI 571 (Gleevec / Glivec©





    /
    protein threonine / tyrosine kinases MAPKK / MEK UO126 
    PD98059 
    LF from Bacillus anthracis
    wee1
    mik1
    protein histidine kinases (only in plants and Bacteria) ETR1, ETR2, EIN4, ERS1, ERS2 (coupled to ethylene receptor)
    CRE1 / AHK4 (coupled to cytokinin receptor)
    CKI1, CKI2 (coupled to cytokinin receptor)
    ATHK1 (osmosensor)
    lipid kinases PI3K
  • class I (+ RasBD)
    • subclass IA (stimulated also by FRP)
      • p110a => PI3Ka
      • p110b => PI3Kb
      • p110d => PI3Kd
      adapters or regulatory subunits : 
    • subclass IB (stimulated by Gbg subunits)
    • adapter or regulatory subunit : 
  • class II (+ C2 domain)
  • class III :
    • VPS34

    • adapter or regulatory subunit : 
    middle t antigen from SV40 LY294002 
    radicicol 
    wortmannin
    diacylglycerol kinase (DAGK)  R59022 
    sphingosine kinase 1 (SphK1)
    sphingosine kinase 2
    N,N-dimethylsphingosine (DMS)
    dihydro-sphingosine (DHS)
    lipid phosphatases IP phosphatase Li+
    protein serine / threonine phosphatase PP1 / PPI glycogen phosphorylase (inhibited) 
    p105Rb (inhibited) 
    p80cdc25 (inhibited) 
    eIF2a (activated) 
    glycogen synthase (activated) 
    IkBa (activated) 
    X (activated or inhibited)
    tautomycin
    tautomycetin (TMC)
    iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-
    okadaic acid (weak inhibition) 
    microcystin-LR
    PP2A / PPIIA tautomycin
    iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-
    okadaic acid (strong inhibition) 
    small t antigen from SV40
    calyculin A
    microcystin-LR
    PP2B / PPIIB / PP3 / PPIII / calcineurin (subunit A / catalytic : a, b or g; subunit B / regulatory : I or II; Ca2+CaM-dependent) T lymphocytes iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-
    cyclosporine A complexed to cyclophilin 40 or neurophilin 
    tacrolimus (acronym for Tsukuba macrolide immunosuppressive) (FK506®) (from Streptomyces tsukubaensis) complexed to FKBP1A / FKBP12 or FKBP4 / FKBP52
    PP2C / PPIIC
    PP4 / PPIV iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-)
    PP5 / PPV iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-)
    PP6 / PPVI iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-)
    PP7 / PPVII iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-)
    protein tyrosine phosphatase (PTP) SHP-1 / PTP-1C / HCP / SHPTP1 / SHP / PTPN6  sodium stilbogluconate (SSG) 
    iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-)
    SHP-2 / PTP-2C / Syp / PTP-1D / SH-PTP2 / PTPN11 iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-)
    hPTP1E / PTPBAS / FAP1 
    PTP2E (Rattus norvegicus
    R-PTP y
    iodoacetic acid 
    sodium orthovanadate 
    sodium pervanadate (VO43-)
    dual specificity protein serine / tyrosine phosphatase DUSP1 / MKP1 / PTPN10
    DUSP2 / PAC1
    DUSP3 / VHR
    DUSP4 / MKP2
    DUSP5
    DUSP6 / MKP3
    DUSP7
    DUSP8
    DUSP9
    DUSP10
    DUSP11
    DUSP12
    DUSP13
    DUSP14
    DUSP15
    DUSP16
    DUSP17 / DUSP19
    VO43-
    protein threonine / tyrosine phosphatase Cdc25 VO43-
    caspases caspase 1 / interleukin-1 converting enzyme (ICE) : 2 20-kDa and 2 10-kDa subunits (monocytes, neutrophils, resting and activated T lymphocytes, placenta tissue and several B-lymphoblastoid cell lines) pro-IL-1b and pro-IL-18 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD) 
    crmA from cowpox virus
    P35 from Baculovirus spp.
    pralnacasan
    caspase 2 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 3 poly (ADP-ribose) polymerase (PARP) Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 4 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 5 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 6 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 7 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 8 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD) 
    Cbz-Leu-Glu-Thr-Asp(OMe) -fluoromethylketone (zLETD)
    caspase 9 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD) 
    Cbz-Leu-Glu-His-Asp(OMe) -fluoromethylketone (zLEHD
    caspase 10 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 11 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 12 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 13 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    caspase 14 Cbz-Val-Ala-Asp(OMe) -fluoromethylketone (zVAD)
    (non-receptor) guanlyate cyclases (GC) guanlyate cyclase 1A2 YC-1 
    isoliquiritigenin
    1H-[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one (ODQ) 
    N-methylhydroxylamine
    adenylate cyclases (AC) AC1 (+ Gas, PKC, Ca2+CaM ;- Gai, Ga0, Gaz, b5g2, b1g2, Ca2+)
    AC2 (+ : PKC; - : b5g2, b1g2
    AC3 (+ : PKC, Ca2+CaM ; - : Gai, Ca2+
    AC4 (+ : ; - : PKC) 
    AC5 (+ : PKC; - : PKA, Ga0, Gai, Gaz, Ca2+), 
    AC6 (+ : ; - : PKA, Ga0, Gai, Ca2+
    AC7 (+ : PKC, Ca2+CaM ; - : ) 
    AC8 (+ : ; - : ) 
    AC9 (+ : ; - : Ca2+)
    ATP => cAMP + PPi forskolin
    forskolin
    forskolin
    forskolin
    forskolin
    forskolin
    forskolin
    forskolin
    /
    phosphodiesterases (PDE) (they all are also inhibited by xanthines (e.g. 
  • aminophylline
  • pentoxyphylline (Trental©
  • propentophylline (Karsivan©

  • ... are inhibitors of TNF-a release in monocytes activated by AGEs) and methylxanthines (e.g. 
  • caffeine / teine
  • teophylline
  • teobromine
  • diphylline
  • enprofylline
  • papaverine )

  • ..., but at concentrations >> those acting on P1 purinoceptors)
    PDE1A
    PDE1B
    PDE1C
    PDE2A
    PDE3A
    PDE3B
    PDE7A
    PDE8A
    PDE9A
    cGMP > cAMP 
    cGMP > cAMP 
    cGMP and cAMP 
    cGMP and cAMP 
    cGMP and cAMP 
    cGMP and cAMP 
    cAMP 
    cNMP 
    cAMP 

    cAMP 
    cAMP 
    cGMP
    vinpocetine (Cavinton®, Remedial®, and Vincaton®
    EHNA 
    milrinone (Primacor®
    inamrinone (Inocor®, Inamrinone Injection®) / amrinone (Amrinone lactate®), SelCIDs
    enoximone (Perfane®
    lixazinone / RS-82856 
    imadozan 
    cilostamide 
    rolipram 
    zaprinast 
    3-isobutyl-1-methylxanthine (IBMX) 
    D-22888 (type IV) 
    zardaverine (type III and IV) 
    vesnarinone / OPS 8212 (Arkin-Z®, Otsuka®
    pimobendan 
    BMY 20844 
    RA233 
    KF19514 (type I and IV) 
    anagrelide / BL-4162A (Agrylin®, Xagrid®, Thromboreductin®) => 2-amino-5,6-dichloro-3,4-dihydroquinazoline / RL603 
    9-(tetrahydro-2-furyl) adenine
    PDE4A
    PDE4B
    PDE4C
    PDE4D
    cilomilast (Amiflo®

    roflumilast 
    PDE5A sildenafil citrate (Revatio®, Viagra®, Vigrex®) (strong inhibitor)
    tadalafil (Cialis®
    vardenafil (Levitra®, Nuviva®
    DA-8159
    PDE6A (photoreceptors) sildenafil citrate (Viagra®, Vigrex®) (weak inhibitor)
    nucleotide metabolism hypoxanthine/guanine phosphoribosyltransferase (HGPRT / HPRT) 
    thymidine kinase 
    deoxyguanosine kinase
    deoxycytosine kinase
    dihydrofolate reductase (DHFR)
  • methotrexate (MTX) / amethopterin sodium (Folex©, Mexate©, Methotrexate®, Rheumatrex©, ...)
  • aminopterin sodium (Aminopterin Sodium©
  • edatrexate / 10-ethyl,10-deaza aminopterin 
  • lometrexol 
  • raltitrexed / ZD1694 (Tomudex©) : intracellularly is polyglutamated to its active form which can be retained in cells for prolonged periods.
  • pemetrexed / multitargeted antifolate (MTA) / LY231514 (Alimta©) for NSCLC, malignant mesothelioma, and other solid tumors
  • trimetrexate (Neutrexin©)
  • adenosine deaminase (ADA)
  • tacrine (Cognex©
  • pentostatin / 2'-deoxycoformycin (Nipent©
  • cladribrine / 2-chlorodeoxyadenosine (2-CdA) (Leustatin©
  • fludarabine (Fludara©
  • erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA)
  • xanthine oxidase (homodimer; converted to xanthine oxidase by irreversible proteolytic modification or reversible thiol oxidation) allopurinol (Allgoric©, Allorin©, Cyploric©, Lopurin©, Zyloric©, Zyloprim©) => oxypurinol
    febuxostat / TMX-67
    ribonucleotide reductase  hydroxyurea / hydroxycarbamide  (Hydrea©, Oncocarbide©
    didox / 3,4-dihydroxybenzohydroxamic acid
    trimidox / 3,4,5-trihydroxybenzamidoxime
    DNA topoisomerases DNA topoisomerase I / Scl-70 camptothecin derivatives
    • topotecan (Hycamtin©)

    • irinotecan / CPT-11 (Camptosar©) => SN-38 
    • 9-nitrocamptothecin (9NC)
    • 9-aminocamptothecin (9-AC)
    • 10,11- methylenedioxycamptothecin 
    DNA topoisomerase II / DNA girase (p170a or p180b) epipodophyllotoxins (synthetic analog of podophyllotoxin
    • teniposide / VM-26 (Vumon©)
    • etoposide / VP-16-213 (Vepesid©, Toposar©, Etopophos©)
    • podophyllin
    • podofilox (Condylox®)
    actinomycin D / dactinomycin (antibiotic) (Cosmegen©
    ICRF-154 
    ICRF-193 
    bleomycin (antibiotic) sulfate (Blenoxane©
    acutissimin A
    lucanthone 
    acridine derivatives : 
    • amsacrine (AMSA PD©)
    anthracycline antibiotics : 
    • annamycin (liposomal : Aronex©)
    • daunorubicin / daunomycin (DNM) / rubidomycin hydrochloride / NSC-82151 (Cerubidine©)
      • pegylated liposomal daunorubicin : DaunoXome©)
    • doxorubicin hydrochloride / NSC-123127 (Adriamycin©, Rubex©, ...; Pharmacia and Upjohn; Peapack, NJ; 
      • pegylated liposomal doxorubicin (PLD) : Caelyx©, Doxil©, Doxilen©, DOX-SL©, Evacet©, LipoDox©,  Myocet©; injections are less cardiomyotoxic
      • ThermoDox© (source : Celsion Corp.) : is a temperature-sensitive liposomal encapsulation activated by radio frequency ablation (RFA), which allows focused delivery of the drug to the liver tumor lesions
    • 4'-iodo-4'deoxydoxorubicin
    • epirubicin / 4'-epidoxorubicin (Ellence©; Pharmacia and Upjohn; Portage, MI)
    • idarubicin (Idamycin®, Zavedos®)
    • mitoxantrone (an anthracenedione) (Novantrone©)
    • pixantrone (BBR 2778) (aza-anthracenedione)
    • sabarubicin / MEN-10755 (the first disaccharide anthracycline)

    • valrubicin (Valstar©)
    • zorubicin (Rubidazone©)
    histone deacetylase (HD / HDAC) histone deacetylase 1 (HDAC1)
    Rpd1 (it binds Sin3 corepressor and Ume6) 
    HDAC inhibitors (HDIs)
    • vorinostat / suberoylanilide hydroxamic acid (SAHA) / NVP-LAQ824 
    • short chain fatty acid sodium butyrate (NaB)
    • trichostatin A (TSA)
    • FK228 / bicyclic depsipeptide FR 901228
    • m-carboxycinnamic acid bis-hydroxamide (CBHA)
    • MS275 / N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide 
    • valproic acid (VPA) (PEAC minitablets©; source: TopoTarget A/S)
    • LBH589 inhibits HDAC6 / tubulin deacetylase (TDAC)
    SIRT1 / Sir2a p53 resveratrol
    histone acetyltransferase (HAT) p300 / CBP
    TAFII250
    GRIP
    GCN5
    PCAF
    pCIP
    SRC-1
    Tip60
    ATPases F0F1 ATPase oligomycin
    myosin ATPase butanedione monoxime (BDM)
    H+ / K+ ATPase (a subunit : gastric or nongastric ; b subunit) (lumenal membrane of parietal cells in stomach) proton pump inhibitors (PPI) : prodrugs activated at pH 1.0 inside the canaliculus of a parietal cell, faster than their serum elimination rate
    • esomeprazole / S-omeprazole (Nexium®)
    • lansoprazole (Prevacid®, Zoton®) binds to cys321, 813 (or 822) and 892
    • omeprazole (racemic) (Antra®, Gastroloc®, Mopral®, Omepral®, Losec® MUPS (Multiple Unit Pellet System) tablets, Prilosec®) binds covalently to 2 cysteine residues at positions 813 (or 822) and 892
    • pantoprazole (Protium®, Protonix®) binds to cys813 and 822
    • rabeprazole (Aciphex®)
    3 Na+ / 2 K+ ATPase palytoxin
    cardiac glycosides (agonists of ouabain-like endogenous factors) : 
    phospholipases phospholipase A1 (PS-specific) removes FA in sn-1 from 1,2- diacylglycero phospholipids
    phospholipase A2 mellitin
    mepacrine 
    4-Br- phenacylbromure
    Bi 
    4-bromophenacylbromide
    phospholipase B
    phospholipase Cb (activated by GqPCRs; found only in Metazoa
    phospholipase Cg (activated by RTKs; found only in Metazoa
    phospholipase Cd1 (activated by Ca2+; found only in Metazoa, plants and yeasts, no PH domain
    phospholipase Ce
    PC-specific phospholipase D1 (PC-specific, PI-4,5-P2 stimulated, oleate inhibited; found in all Eukarya
    GPI-specific phospholipase D1
    phospholipase D2
    ANRP GrpE
    AAP DnaJ
    Ras-like superfamily Arf family  Rap family 
    Rab family 
    Rho family  Rac family 
    Ran family
    Ras family 
    TAT-C3
    GNRP / GEF / GDS Dbl 
    TIAM1
    GRF1 (Ca2+-CaM-dependent) 
    GRF2 / Epac / C3G
    EF-Ts
    eIF2B  RCC 
    Smg25 
    SOS1
    VAV1
    VAV2
    VAV3
    GAP Rho/Rac GAP 
    RhoGAP1 / p50
    RhoGAP4 / p115
    RhoGAP5 / p190
    RhoGAP6 (5 isoforms) 
    chimerin 1 / n-chimaerin
    chimerin 2 / b chimaerin
    Rap1-GAP 
    RASA1 / p120GAP
    RASA2 / RasGAP 2
    IQGAP-1 
    NF1 / neurofibromin 1
    IRA1 
    IRA2
    Rho, Rac 
    Rho 
    Rho 
    Rho 
    RhoA 
    Rac 
    Rac 
    Rap1
    Ras 
    Ras
    Ras 
    Ras
    Ras
    Ras
    GEF & GAP BCR (also Ser/Thr kinase) Rho / Rac
    GDI RhoGDIa Rho
    RhoGDIb
    RhoGDIg
    membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG) fatty acid cyclooxygenase (COX) => PGH synthase (PGHS) 1 (active site : Val; monotopically inserted in the ER and nuclear membrane with the substrate-binding pocket precisely orientated to take up released arachidonic acid, constitutive)
    • COX-1 (GI tract, kidney, platelets)
    • partial COX-1 (PCOX-1)
    • COX-3 (GI tract, heart and aorta)
    Can form homodimers or heterodimers with COX-2ref
    5,8,11,14-eicosatetraynoic acid 
    nonsteroidal antiinflammatory drugs (NSAIDs)
    • alkanones
      • nabumetone (Relafen®)
    • tenidap (Enablex®
    • azapropazone / apazone (Rheumox®)
    • acetanilide => p-aminophenol => phenacetin / acetophenetidin => acetaminophen / paracetamol / N-acetyl-p-aminophenol (Acetanol®, Liquiprin®, Panadol®, Perfalgan®, Tachipirina®, Tylenol®; Talcen® in combination with pentazocine; Percocet® and Tylox® in combination with oxycodone; Co-efferalgan® in combination with codeine; Mersyndol®

    • in combination with codeineand doxylamine; Algosil®, Antinevralgico Knapp®, Antireumina®, Drin®, Neocibelgina®, Neonevral®, Neonisidina®, Verdal® in combination with acetylsalicylic acid and caffeine) (on COX-3 only: antipyretic but not antiinflammatory as WBC-derived peroxides inhibit it) 
    • propacetamol
    • salicylates 
      • salicylic acid choline (Arthropan®), magnesium (Magan®), or both (Buf-Puf®, Trilisate®, ...)
      • acetylsalicylic acid (ASA) (irreversible inhibitor by covalently acetylating Ser529) (Ascriptin®, Aspirin®, Aspirinetta®, Aspisevt®, Cardioaspirin®, Empirin®, Ecotrin®, Entrophen®, Genuine Bayer®, Halfprin®; Aggrenox® in combination with dipyridamole; Talwin Compound® in combination with pentazocine; Percodan®, ... in combination with oxycodone)
        • lysine acetylsalicylate (Aspegic®, Aspidol®, Cardirene®, Flectadol®) : less gastrolesive (basic salt)
      • benorilate
      • diflunisal (Dolobid®)
      • mesalamine / 5-aminosalicylic acid (Asacol®, Claversal®, Salofalk®, Salofalk® Granu-Stix®, Pentacol®, Pentasa®, Rowasa®)
      • methyl salicylate
      • olsalazine (Dipentum®) : 2 molecules of mesalamine bound together with an azo bond
      • salsalate / salicylsalicylic acid (Disalcid®, Salflex®)
      • sulfasalazine / salicylazosulfapyridine
      • choline magnesium trisalicylate (Trilisate®)
    • acetic acids 
      • phenylacetic acids
        • alclofenac (Prinalgin®)
        • diclofenac (Cataflam®, Voltarin®, Voltarin-XR®, Voltaren®, Arthrotec®(together with misoprostol))
        • fenclofenac / 2-(2,4-dichlorophenoxy)

        • phenylacetic acid (Flenac®
        • tolmetin (Tolectin®)
        • ketorolac (Acular®, Lixidol®, Toradol®)
      • carbo- and heterocyclic
        • acermetacin (Emflex®)
        • etodolac (Lodine®, Lodine XL®)
        • indometacine / indomethacin (Difmetre®, Difmetre mite®, Imet®, Indocid®, Indocin®, Indocollirio®, Indom®, Indoxen®, Indoxen forte®, Liometacen®, Metacen®)
        • oxaprozin (Daypro®)
        • sulindac (Clinoril®)
    • propionic acids 
      • benoxaprofen (Bexopron®)
      • carprofen (Rimadyl®)
      • dexibuprofen (Seractil®)
      • fenbufen (Cinopal®)
      • fenoprofen (Nalfon®)
      • flurbiprofen (Ansaid®, Ocufen®)
      • ibuprofen (Advil®, Buscofen®, Brufen®, Ibifon®, Ibren®, Ibuphil®, Ibuprin®, Ibuprohm®, Iburam®, Ibu-tab®, Ibutop®, Motrin®, Moment®, Neocybalgin®, Nuprin®, Cibalginadue®)
      • indobufen (Ibustrin®)
      • ketoprofen (Fastumgel®, Orudis®, Oruvail®)
      • naproxen (Aleve®, Anaprox®, Naprosyn®; Trexima® in combination with sumatriptan)
      • oxaprozin (Daypro®)
      • pirprofen
      • suprofen (Profenal®)
      • tiaprofenic acid (Surgaml®)
    • fenamates / N-phenylanthranilic acids 
      • flufenamic acid
      • meclofenamic acid (Arquell®, Movens®)
      • mefenamic acid (Ponstel®)
    • pyrazolones 
      • aminopyrine => ampyrone
      • antipyrine (Auralgan® in combination with benzocaine)
      • dipyrone / methamizole (Novalgina®)
      • oxyphenbutazone (Tandearil®)
      • phenylbutazone (Alindor®, Alkabutazona®, Alqoverin®, Anerval®, Anpuzone®, Antadol®, Anuspiramin®, Arthrizin®, Artrizin®, Artrizone®

      • Artropan®, Azdid®, Azobutil®, Benzone®, Betazed®, Bizolin 200®, B.T.Z.®, Butacote®, Butacompren®, Butadion®,  Butadiona®, Butadione®, Butagesic®, Butalgina®, Butalan®, Butalidon®, Butaluy®, Butaphen®, Buta-Phen®, Butapirazol®, Butapyrazole®, Butarecbon®, Butartril®, Butartrina®, Butazina®
        Butazolidin®, Butazolidine®, Butazona®, Butazone®, Butidiona®, Butiwas-simple®, Butone®, Butoz®, Butylpyrin®, Buvetzone®, Buzon®, Chembutazone®, Digibutina®, Diossidone®, Diozol®, Diphebuzol®, Diphenylbutazone®, Ecobutazone®, Elmedal®, Equi Bute®, Eributazone®, Esteve®, Febuzina®, Fenartil®, Fenibutasan®, Fenibutazona®, Fenilbutazona®, Fenylbutazon®, Fenilbutina®, Fenilbutine®, Fenibutol®, Fenilidina®, Fenotone®, Flexazone ®,
        G 13,871®, IA-But®, Intalbut®, Intrabutazone®, Ipsoflame®, Kadol®, Lingel®, Malgesic®, Mephabutazone®, Merizone®, Nadazone®, Nadozone®, Neo-Zoline®, Novo-phenyl®, Phebuzin®, Phebuzine®, Phen-Buta-Vet®, Phenbutazol®, Phenopyrine®, Phenylbetazone®, Phenylbutaz®, Phenylbutazonum®, Phenyl-mobuzon®, Pirarreumol B®, Praecirheumin®, Pyrabutol®, Pyrazolidin®, Rectofasa®, Reudo®, Reudox®, Reumasyl®, Reumazin®, Reumazol®, Reumune®, Reupolar®, Robizon-V®, Rubatone®, Scanbutazone®, Schemergin®, Shigrodin®, Tazone®, Tetnor®, Tevcodyne®, Therazone®, Ticinil®, Todalgil®, Uzone®, VAC-10®, Wescozone®, Zolaphen®, Zolidinum®,)
      • propyphenazone / propifenazone / 4-isopropylantipyrine / isopropylphenazone

      •  (Cistalgan® in combination with flavoxate)
    • enolic acids 
      • oxicam 
        • ampiroxicam
        • cinnoxicam (Sinartrol®)
        • droxicam
        • isoxicam
        • lornoxicam (Xefo®)
        • meloxicam (the one with the lowest COX-2 IC50 / COX-1 IC50 rate, so usable as a COX-2 selective inhibitor) (Mobic®)
        • piroxicam (Feldene®)
        • pivoxicam
        • sudoxicam
        • tenoxicam (Tobitil®)
    fatty acid cyclooxygenase 2 (COX2) / PGH synthase 2 (PGHS2) (active site : Ile; monotopically inserted in the ER and nuclear membrane with the larger substrate-binding pocket precisely orientated to take up released arachidonic acid) => 
    • COX-2b (inducible)
    • COX-2 (constitutive : macula densa, thick ascending limb of Henle loop, podocytes, interstitial papillary cells of kidneys, certain brain regions => involved in renal water and electrolyte balance, gastric cytoprotection, and platelet aggregation)
    • COX-2 (inducible by various inflammatory insults in monocytes or mast cells or by shear stress in endothelium)
    Can form homodimers or heterodimers with COX-1ref
    COX-1 antagonists
    acetanilide => p-aminophenol => phenacetin / acetophenetidin => acetaminophen / paracetamol / N-acetyl-p-aminophenol  (Tachipirina®, Tylenol®; Talcen® in combination with pentazocine; Percocet® and Tylox® in combination with oxycodone; Co-efferalgan® in combination with codeine) (on COX-2b only) 
    NS-398 
    DFP [3-(2-propyloxy) -(4-methyl-sulphonylphenyl)- (5,5-dimethyl)-furanone] 
    COX-2 selective inhibitors (CSI) block the cyclooxygenase activity of PGHS2, but do not affect the associated peroxidase function
    • sulfonanilides
      • nimesulide (Aulin®)
    • SC-58125 / SC-57666 
    • BF-389 
    • L743337 
    • flosulide 
    • indole acetic acids 
      • etodolac (Lodine®)
    • coxibs :
      • 1st generation coxibs :
        • diaryl-substituted pyrazoles 
          • celecoxib (Celebrex®)
          • OSU03012
        • diaryl-substituted furanones 
          • rofecoxib (Arofexx®, Vioxx®)
      • 2nd generation coxibs :
        • valdecoxib (Bextra®)
        • etoricoxib (Arcoxia®, Tauxib®)ref1, ref2 : its long plasma half-life allows for once-daily oral dosing; the highest recommended daily dose for chronic use is 90 mg for rheumatoid arthritis and 60 mg for osteoarthritis and chronic low back pain. The recommended daily dose for acute pain relief treatment from primary dysmenorrhea and acute gouty arthritis is 120 mg;  same efficacy as non-COX-2 selective NSAID, with fewer gastro-intestinal adverse effects
        • deracoxib (Deramaxx®)
        • lumiracoxib (Prexige®)
    PGD2 synthase / PGH2 isomerase (hematopoietic)
    PGD2 synthase / PGH2 isomerase (brain)
    a-ketoreductase, family 1, member C3 / PGF2a synthase (uterus)
    microsomal PGE2 synthase (mPGES) / PGH2 isomerase
    15-hydroprostaglandin dehydrogenase
    thromboxane A2 synthase (platelets, macrophages, lung, spleen) dazoxiben 
    ozagrel (OKY-046, (E)-3-(4-(1-imidazolylmethyl)phenyl)-2-propenoic acid) 
    ridrogrel 
    trapidil
    BM-567 (N-pentyl-N'-[(2- cyclohexylamino-5-nitrobenzene) sulfonyl]urea) 
    picotamide (N,N'bis(3-pyridinylmethyl)-4-methoxy-isophthalamide) (Plactidil®)
    prostacycline synthase (endothelial cells, lung, spleen)
    arachidonate 5-lipoxygenase (5-LO / 5-LOX) / LTA4 synthase (nonheme iron dioxygenase; with Ca2+ and ATP translocates to the nuclear envelope from either the nuclear or cytoplasmic compartment. FLAP, a small resident nuclear envelope integral protein, acts as an apparent arachidonic acid transfer protein and facilitates presentation (WBCs : mast cell, macrophage, ...) arachidonic acid => LTA4 zileuton (Zyflo®
    boswellic acid
    esculetin 
    5,8,11,14-eicosatetraynoic acid 
    w-3 fatty acids (OmegaBrite®, Fisol®
    • eicosapentanoic acid (EPA)
    • docosahexanoic acid (DHA)
    • octadecatetraenoic acid
    5-LOX-activating protein (FLAP) MK-886
    arachidonate 8-lipoxygenase (8-LOX) 5,8,11,14-eicosatetraynoic acid
    arachidonate 12-lipoxygenase (12-LOX) (platelets, WBCs) 5,8,11,14-eicosatetraynoic acid
    arachidonate 15-lipoxygenase (15-LOX) 5,8,11,14-eicosatetraynoic acid
    LTA4 hydrolase (LTA4H) (a catalytic domain highly related to thermolysin and a COOH-terminal domain with armadillo-like repeats points to an interesting evolutionary heritage : because LTA4H is found in yeast, predating the appearance of other leukotriene biosynthetic enzymes, it may have had, at one time, exclusively aminopeptidase or other noneicosanoid related functions) LTA4 => LTB4 SC57461A 
    bestatin
    LTB4 12-hydrodehydrogenase
    LTC4 synthase (a FLAP-like protein found in the nuclear envelope) LTA4 => LTC4 MK0591
    MGST2
    MGST3
    g-glutamyl- transpeptidase (gGT) 1 (in Mus musculus g-glutamyl leukotrienase (GGLT) / g-glutamyltransferase-like activity 1) LTC4 => LTD4 acivicin
    g-glutamyl- transpeptidase (gGT) 2
    GGTLA1
    GGTLAL1
    glutathione synthase
    glutathione S-transferase (GST) :
    • m1 (GSTM1)
    • t1 (GSTT1)
    • p1 (GSTP1)
    buthionine-(S,R)-sulfoximine (BSO)
    neurotrasmitter anabolism indoleamine 2,3-dioxygenase (IDO) Trp 1-methyltryptophan
    tryptophan 3-monooxygenase In mice 2 isoforms of typtophan hydroxylase-2 (Tph2), an enzyme that governs the manufacture of serotonin, exist : serotonin levels differ by 50-70% between animals with one or other of the variants 
    tyrosine hydroxylase Tyr => DOPA a-methyltyrosine / metyrosine (Demser®)
    aromatic L-amino acid decarboxylase (DOPA decarboxylase)
    • DOPA => DA 
    • 5-hydroxytryptophan (oxitriptan (5-HTP) (Levotonine®, Pretonine®, Serotonyl®, Triptene®) => 5-HT
    DOPA decarboxylase inhibitors (DDI)
    • carbiDOPA (Lodosyn®; in combination with L-DOPA in Atamet®, Sinemet®, Sinemet CR®) ; 
    • benserazide (+ L-DOPA = Madopar®
    • L-a-methylDOPA (competitive inhibitor)
    histidine decarboxylase His => histamine a-fluoromethylhistamine (irreversible inhibitor)
    histamine-N-methyltransferase (HMT) histamine metoprine
    neurotransmitter catabolism acetylcholinesterase (AChE) ACh => acetate + choline neurons, erythrocytes acetylcholinesterase inhibitors (AChEIs) :

    onchidal
    fasciculins 
    huperzine A
    tacrine
    1,5-bis(4-allyldimethylammoniumphenyl)pentan-3-one dibromide (BW284c51) 
    noncovalent inhibitors :

    • edrophonium chloride (Tensilon®, ...)
    • tacrine / 1,2,3,4-tetrahydro-9-aminoacridine (Cognex®)
    • donepezil (Aricept®)
    "reversible" carbamate inhibitors 
    • eserine / physostigmine salicylate (Antilirium®) or sulfate
    • phenserine
    • neostigmine bromide or methylsulfate (Prostigmin®)
    • pyridostigmine bromide oral (Mestinon®) or parenteral (Regonol®, Mestinon®)
    • demecarium bromide (Humorsol®)
    • galantamine (Nivalin®, Razadyne®, Reminyl®)
    • rivastigmine (Exelon®, Excelon®)
    • carbamate insecticides
      • aldicarb (Temik®)
      • bendiocarb (Dycarb®, Trumpet®)
      • carbaryl (Sevin®)
      • carbofuran
      • dimetilan
      • isolan
      • methiocarb (Draza®, Bayer UK892®)
      • methomyl
      • pirimicarb (Aphox®, Pirimor®, Rapid®)
      • propoxur (Baygon®)
    organophosphorus 
    • group A, X = halogen, cyanide, or thiocyanate leaving group
      • diisopropyl fluorophosphate (DFP), isofluorophate
      • nerve gases of the G series
        • tabun (GA) / ethyl N-dimethyl phosphoramidocyanidate
        • sarin (GB) / O-isopropyl methylphosphonofluoridate
        • soman (GD) / pinacolyl methylphosphonofluoridate
        • GE
        • cyclohexyl sarin (GF)
    • group B, X = alkylthio, arylthio, alkoxy, or aryloxy leaving group
      • paraoxon / E 600 / O,O-diethyl O-(4-nitrophenyl)-phosphate (Mintacol®)
      • malaoxon / O,O-dimethyl S-(1,2-dicarboxyethyl)- phosphorothioate
      • metrifonate => dimethyl 2,2-dichlorovinyl phosphate (DDVP)
      • pirimiphos-methyl (Actellic D®, Actellic 2% dust®)
      • nerve gases of the V series
        • VE
        • VG
        • V-Gas
        • VM
        • VX / O-ethyl S-(2-diisopropyl aminoethyl) methylphosphonothiolate : absorbed through skin, 99% is degraded within 15 hours on concrete due to very high pH
    • group C, thionophosphorus or thio-thionophosphorus compounds
      • phosphorothioate insecticides
        • parathion / O,O-diethyl O-(4-nitrophenyl)- phosphorothionate (Etilon®) => paraoxon
        • methyl parathion
        • malathion / O,O-dimethyl S- (1,2-dicarbethoxyethyl) -phosphorothionate (Chemathion®, Fyfanon®, Mala-Spray®, Malathion®, Prioderm®) => malaoxon
        • diazinon / dimpylate / O,O-diethyl O-(2-isopropyl-6-methyl -4-pyridinyl)-phosphorothionate (Diazinon®, Knox-out®, Spectracide®)
        • chlorpyrifos / O,O-diethyl O-(3,5,6-trichloro-2 -pyridyl) -phosphorothionate (Dursban®, Lorsban®)
        • chlorpyrifos-methyl (Reldan 22®, Greencrop®, Storeclean®)
        • phosphamidon
        • monocrotophos
        • disulphoton phorate
      • dichlorvos (DDVP®, Vapona®, Vaponite®)
      • dithiophosphorus compounds
        • dimethoate (Cygon®, De-Fend®, Rogor®)
    • group D, pyrophosphates and similar compounds
      • tetraethyl pyrophosphate (TEPP) (Kilmite-40®, Tetron®, Vapotone®)
    • group E, quaternary ammonium compounds
      • echothiophate / MI-217 / diethoxyphosphinylthiocholine iodide (Phospholine Iodide®)
    • azinphos-methyl
    • bromophos-ethyl
    • bromophos
    • carbophenothion
    • chlorphenvinphos
    • cythioate
    • demeton-S-methyl
    • fenitrothion
    • fenthion (Lebaycid®)
    • formothion
    • heptenophos
    • jodphenphos (iodofenphos)
    • mevinphos
    • phorate
    • phosmet
    • phoxim
    reactivators 
    • hydroxylamine
    • hydroxamic acids
    • oximes
      • pyridine-2-aldoxime methyl chloride (2-PAM) / pralidoxime chloride (Protopam Chloride®)
      • pralidoxime methylsulfate (Contrathion®)
      • obidoxime (Toxogonin®)
      • HI-6
    nostocarboline
    MAO-A (in outer membranes of mitochondria of noradrenergic and dopaminergic CNS neurons, cardiomyocytes, hepatocytes, enterocytes, muscularis mucosae and muscular layers of duodenum, endothelial cells of lymphatic vessels, muscular layers and fibroblasts of arteries and veins, renal tubuli, collecting ducts and the Bowman's capsule) DA
    NE
    5-HT
    irreversible ("classical") MAO inhibitors (MAOI) (bind to FAD site) 
    • acetylenic agents / methylbenzylpropinylamine
      • clorgyline
      • pargyline (Eutonyl®, Eudatine®, TenalinPaxil, Seroxat, Aropax, Deroxat )
    • hydrazines
      • benmoxine (Neuralex®, Nerusil®)
      • brofaromine
      • isocarboxazide (Marplan®, Enerzer®, Marplon®
      • iproniazid (Marsilid®, Iprozid®, Ipronid®, Rivivol®, Propilniazida®)
      • iproclozide (Sursum®
      • mebanazine (Actomol®)
      • nialamide (Niamid®, Espril®, Isalizina®, Surgex®)
      • phenelzine (Nardil®, Stinerval®, Monofen®, Fenelzin®, Kalgan®, Nardelzine®)
      • pheniprazine
      • phenoxypropazine (Drazine®
    • indolalkylamine
      • etryptamine (Monase®)
    • phenylcyclopropylamine
      • tranylcypromine (Parnate®, Parmodalin®, Sicoton®, Transamin®, Transapin®, Tylciprine®)
    • pyrimidine
      • safrazine (Safra®)
    reversible inhibitors of MAO (RIMA)
    • benzamide derivatives
      • moclobemide (Aurorix®, Manerix®, Moclamine®
    • benzoxazine
      • caroxazone 
    • methylphenethylamine
      • amiflamine 
    • oxazolidinone
      • cimoxatone 
      • toloxatone (Humory, Perenum®)
    • piperidine
      • brofaromine (Consonar®)
    • pyrazino carbazole
      • pyrazidole / pirlindole 
    • pyrazino-indole tetracyclic
      • tetrindole (a tetracyclic antidepressant)
    • incazane 
    MAO-B  (in mitochondria of serotonergic neurons, cardiomyocytes, hepatocytes, enterocytes, muscularis mucosae and muscular layers of duodenum, muscular layers and fibroblasts of arteries and veins, renal tubuli, platelets) phenethylamines selegiline / l-deprenyl (Eldepryl®, Carbex®, Atapryl®, Lesotal®, Eldeprine®, Movergan®, Jumex®, Jumexal®, Plurimen®
    phenelzine (Nardil®, Stinerval®, Monofen®, Fenelzin®, Kalgan®, Nardelzine®
    nialamide (Niamid®, Espril®, Isalizina®, Surgex®
    tranylcypromine (Parnate®, Parmodalin®, Sicoton®, Transamin®, Transapin®, Tylciprine®)
    catechol-O- methyltransferase (COMT) L-DOPA=> 3-O-methyldopa (3-OMD) tolcapone (Tasmar®
    entacapone (Comtan®, Comtess®)
    GABA transaminase (GAT) vigabatrin / g-vinyl-GABA (Sabril®)
    valproic acid / n-dipropyl acetate (Depakene®, Convulex®, Depakine®, Depalept®, Epilim®, Ergenyl®, Leptilan®, Orfiril®, Valporal®) or valproate (Depakote®, Epival®, Elvetium®, Everiden®, Novoseven®, Valcote®, Valnar®) or sodium valproate (Depacon®, Valpro®)
    succinate semialdehyde dehydrogenase (SSAD) valproic acid / n-dipropyl acetate (Depakene®, Convulex®, Depakine®, Depalept®, Epilim®, Ergenyl®, Leptilan®, Orfiril®, Valporal®) or valproate (Depakote®, Epival®, Elvetium®, Everiden®, Novoseven®, Valcote®, Valnar®) or sodium valproate (Depacon®, Valpro®)
    fatty acid aminohydrolase (FAAH) phenylmethylsulfonyl fluoride
    methyl-arachidonoyl fluorophosphonate 
    dipeptidyl-dipeptidase (DAP) / CD10 / CALLA / neutral endopeptidase (NEP) / enkephalinase / neprilysin b-amyloid thiophan (N-(a-benzyl-b-thio-propionyl)glycine) 
    vasopeptidase inhibitors (VPI)
    candoxatril 
    acetorphan / racecadotril
    LAF237 
    NN7201
    P93/01
    talabostat mesylate (PT-100), the amino boronic dipeptide Val-boro-Proref
    a-glucosidase intestinal epithelial cells acarbose (Glucobay®, Precose®
    miglitol (Glyset®)
    serine proteases (including tryptase, amylase and phospholipase A2 in pancreatic juice) 6- (or e-) aminocaproic acid (ACA) (Amicar®
    tranexamic acid (TA) (Cyclocapron®, Cyclokapron®, Tranex®, Transamin®, Ugurol®
    aprotinin / bovine pancreatic trypsin inhibitor (BPTI)
    camostat mesilate (CM) / FOY-305 (p.o.) 
    gabexate mesilate 
    nafamostat mesilate 
    sepimostat mesilate
    ulinastatin
    chymase 1 mast cells angiotensinogen
    angiotensin I
    prorenin / big renin => renin juxtaglomerular cells (JGC) in the walls of afferent arterioles of renal glomeruli when ... 
    • increased NaCl reapsorption in the proximal tubule (decreased pressure natriuresis) => decreased tubular delivery of Cl- to macula densa => upregulation of nNOS => peroxynitrite activates COX-2 => PGs activate JGC 
    • drop in blood pressure in afferent arteriole => stretch-activated ion channels in JGC
    • orthosympathetic system activates b1-ARs on JGC
    angiotensinogen
    synthetic tetradecapeptide renin substrate (TDP; Asp-arg-val-tyr-ile-his-pro-phe-his-leu-leu-val-tyr-ser) 
    renin binding protein (RBP)
    aliskiren / SPP100 
    remikiren 
    enalkiren 
    pepstratin A
    angiotensin I-converting enzyme (ACE) / kininase II / dipeptidyl carboxypeptidase / CD143 : ACE also has a GPI-anchored protein releasing activity (GPIase activity). Unlike its peptidase activity, GPIase activity is weakly inhibited by the tightly binding ACEI and not inactivated by substitutions of core amino acid residues for the peptidase activity, suggesting that the active site elements for GPIase differ from those for peptidase activity. ACE shed various GPI-anchored proteins from the cell surface, and the process was accelerated by the lipid raft disruptor filipin. The released products carried portions of the GPI anchor, indicating cleavage within the GPI moiety. Further analysis by HPLC-MS predicted the cleavage site at the mannose-mannose linkage. GPI-anchored proteins such as TESP5 and PH-20 were released from the sperm membrane of wild-type mice but not in Ace knockout sperm in vivo. Moreover, peptidase-inactivated E414D mutant ACE and also PI-PLC rescued the egg-binding deficiency of Ace knockout sperms, implying that ACE plays a crucial role in fertilization through this activityref.
  • somatic isozyme : endothelial cells of lung capillaries
  • testis-specific isozyme : developing spermatids and mature sperm 
  • angiotensin I => angiotensin II
  • BK
  • substance P
  • ACE inhibitors (ACEI) : prodrug (drug) : -pril (-prilat) 
    • sulphydrylic ACEIs
      • alacepril (Cetapril®)
      • altiopril calcium / MC-838
      • captopril (Capoten®)
      • zofenopril (Zofenil®, Zoprace®; Zopranol®, long-lasting action)
    • carboxylic ACEIs
      • benazepril (Lotensin®) (benazeprilat) 
      • cilazapril (Inhibace®)
      • delapril hydrochloride (Adecut®)
      • enalapril (Vasotec®) (enalaprilat) (Vasotec Injection®)
      • lisinopril (Prinivil®, Zestril®; Zestoretic® in combination with hydrochlorothiazide
      • moexipril (Univasc®) (moexiprilat)
      • perindopril (Aceon®) (perindoprilat)
      • quinapril (Accupril®) (quinaprilat)
      • ramipril (Altace®, Quark®) (ramiprilat)
      • spirapril (Renomax®) (spiraprilat) 
      • trandolapril (Mavik®, Odrik®)
      • stiff lactamic
        • cilazopril (cilazoprilat)
    • phosphorylic ACEIs :
      • ceranapril
      • fosinopril sodium (Monopril®)
    • monomamide cyclomethylenic ACEIs
      • idropril
    • imidapril hydrochloride (Tanatril®)
    • temocapril hydrochloride (Acecol®
    vasopeptidase inhibitors (VPI) inhibit both ACE and neutral endopeptidase (NEP)-24.11, further reduce BK metabolism and increase vasodilator natriuretic peptides and thus may have better cardioprotective effects than ACEI : 
    • gemopatrilat 
    • omapatrilat / BMS-186716 (Vanlev®)
    • sampatrilat / UK 81252
    • fasidotril
    ACE2 renal and cardiovascular tissues (including arterial and venous endothelial cells), surface of cells in the lung, gastrointestinal system (ileum, duodenum, jejunum, caecum and colon) angiotensin I => angiotensin II
    g-glutamyl carboxylase Glu => g-carboxy-Glu / Gla (Ca2+-chelating) 

    osteocalcin
    factor II
    factor VII
    factor IX 
    factor X
    GAS6
    matrix Gla protein
    protein C
    protein S
    protein Z
    PRGP1
    PRGP2
    TMG3
    TMG4

    vitamin K analogues that inhibit 2,3-epoxide reductase activity : 
    • 4-hydroxycoumarin derivatives :
      • acenocoumarol / nicoumalone (Sinthrome®, Sintron®, Sintrom®)
      • phenprocoumon (Marcumar®)
      • dicumarol / bishydroxycoumarin
      • warfarin sodium (Aldocumar®, Coumadin®, Panwarfin®, Warfilone®) : p.o., i.v.
    • indan-1,3-dione derivatives :
      • anisindione (Miradon®)
      • phenindione (Dindevan®, Pindione®)
    • rodenticides (agents of accidental or intentional poisoning)
      • bromadiolone
      • brodifacoum
      • chlorophacinone (Rogar X®)
      • diphacin
      • diphenadione
      • dicoumeral
      • fumarin
      • pindone
      • pival
      • racuman
      • ratafin
      • rodefin
      • tomorin
      • 0.25% warfarin
    prekallikrein ==factor XIIa==> kallikrein B / Fletcher factor (plasma) aprotinin (Trasylol®)
    kallikrein 1 (renal / pancreatic / salivary)
    kallikrein 2 (prostate)
    kallikrein 3 / PSA (prostate)
    kallikrein 4 (prostate / enamel matrix)
    kallikrein 5
    kallikrein 6
    kallikrein 7
    kallikrein 8
    kallikrein 9
    kallikrein 10
    kallikrein 11
    kallikrein 12
    kallikrein 13
    kallikrein 14
    kallikrein 15
    heme oxygenase heme oxygenase 1 (HO-1) / hsp32 (inducible)  curcumin (up-regulates expression) 
    caffeic acid phenethyl ester (CAPE) (up-regulates gene expression)
    Zn-(II)-protoporphyrin (ZnPP)
    heme oxygenase 2 (HO-2) (constitutive)
    heme oxygenase 3 (HO-3) (in Rattus norvegicus, constitutive)
    carbonic anhydrase I
    carbonic anhydrase II (cytoplasmic kidney) -zolamides : 
    • acetazolamide (Diamax®, Diamox®
    • dichlorphenamide (Daranide®
    • methazolamide (Neptazane®
    • dorzolamide hydrochloride (Trusopt®
    • brinzolamide (Azopt®)
    carbonic anhydrase III
    carbonic anhydrase IV (lumenal and basolateral membranes of pulmonary (and certain other) capillaries and of proximal renal tubules)
    carbonic anhydrase V
    carbonic anhydrase VI
    carbonic anhydrase VII
    carbonic anhydrase VIII
    carbonic anhydrase IX
    carbonic anhydrase X
    carbonic anhydrase XI
    carbonic anhydrase XII (kidney, colon, pancreas)
    thyroid peroxidase (TPo) (thyroid) thioureylenes / thionamides:
    • thiouracil
    • 6-methyl-2-thiouracil
    • 6-n-propylthiouracil (PTU) (Mercazole®, Thyrozole®, PTU®)
    • methimazole / 1-methyl-2-mercaptoimidazole (MMI) (Tapazole®)
    • carbimazole (Neo-Mercazole®)
    type 1 5a-reductase (neutral to basic pH optimum; not detectable in the fetus, transiently expressed in newborn skin and scalp, permanently expressed in skin (sebaceous glands) from the time of puberty) testosterone => dihydrotestosterone (DHT) finasteride (Propecia®, Proscar®) (high doses)
    type 2 5a-reductase (transiently expressed in skin and scalp of newborns, predominant isozyme detectable in fetal genital skin, in male accessory sex organs, and in the prostate) finasteride (Propecia®, Proscar®) (low doses)
    3b-hydroxysteroid dehydrogenase (HSD3B) pregnenolone => progesterone trilostane
    11b-hydroxysteroid dehydrogenase
    • HSD11B1 [liver, brain, adipose tissue, lung, and other glucocorticoid-target tissues]
    • HSD11B2
  • inactive cortisone => active cortisol

  •  
  • active aldosterone => inactive 11-keto derivative
  • active cortisol => inactive cortisone
  • 17b-hydroxysteroid dehydrogenase
    d-aminolevulinate dehydratase lead (Pb)
    ferrochelatase lead (Pb)
    alcohol dehydrogenase (ADH) 
    • class I : homo- or heterodimers of the following subunits
    • class I : homodimer of p
    • class III : homodimer of c
    • class IV : homodimer of m/d
    • class V : homodimer of m/d
    ethanol = 100 methanol  4-methylpyrazole / fomepizole (Antizol®)
    aldehyde dehydrogenase (AlDH)  calcium carbimide (Dipsan®, Temposil®)
    calcium cyanamide
    disulfiram / tetraethylthiuram disulfide (Antabuse®, Alcophobin®, Anticol®, Aversan®, Etiltoxdivalproex sodium ) : several active metabolytes of the drug, especially diethylthiomethylcarbamate
    aconitase 1 (soluble)  sodium fluoroacetate and fluoracetamide are incorporated into fluoroacetyl-CoA, which condenses with oxaloacetate to form fluorocitrate, the final inhibitor

    aconitase 2  (mitochondrial)
    nitric oxide synthase (NOS) NOS1 / constitutive NOS (cNOS)
  • aminoguanidine sulfate ; 
  • N-iminoethyl-L-lysine ; 
  • NG-methyl-L-arginine (L-NMMA) /  L-NG-nitrosoarginine methyl ester (L-NAME) 
  • 6-anilino-5,8-quinolinequinone / LY83583 / LY 
  • asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of NOS. ADMA inhibits vascular NO production in concentrations found in pathophysiological conditions; ADMA also causes local vasoconstriction when it is infused intraarterially. Thus, elevated ADMA levels may explain the "L-arginine paradox," i.e., the observation that supplementation with exogenous L-arginine improves NO-mediated vascular functions in vivo, although its baseline plasma concentration is about 25-fold higher than the Michaelis-Menten constant Km of the isolated, purified endothelial NO synthase in vitro. The biochemical and physiological pathways related to ADMA are well understood: dimethylarginines are the result of degradation of methylated proteins; the methyl group is derived from S-adenosylmethionine. Both ADMA and its regioisomer, symmetric dimethylarginine, are eliminated from the body by renal excretion, whereas only ADMA is metabolized via hydrolytic degradation to citrulline and dimethylamine by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). DDAH activity and/or expression may therefore contribute to the pathogenesis of endothelial dysfunction in various diseases. Plasma ADMA levels are increased in humans with hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, and chronic heart failure. Increased ADMA levels are associated with reduced NO synthesis as assessed by impaired endothelium-dependent vasodilation. In several prospective and cross-sectional studies, ADMA evolved as a marker of cardiovascular risk. With increasing knowledge of the role of ADMA in the pathogenesis of cardiovascular disease, ADMA is becoming a goal for pharmacotherapeutic interventions. Among other potential strategies that are currently being tested, administration of L-arginine has been shown to improve endothelium-dependent vascular functions in subjects with high ADMA levels. Finally, ADMA has gained clinical importance recently because several studies have shown that ADMA is an independent cardiovascular risk factorref
  • L-NNA 
  • methylene blue
  • NOS2 / inducible NOS (iNOS)
    NOS3 / endothelial NOS (eNOS)
    arginase 1 Nw-hydroxy-L-arginine 
    Nw-hydroxy-nor-L-arginine
    suppressor of cytokine signaling (SOCS) / cytokine-induced STAT inhibitor (CIS) / STAT-induced STAT inhibitor (SSI) family (SH2 domain and SOCS box) SOCS1
    SOCS2
    SOCS3
    SOCS4 / SOCS6
    SOCS5
    SOCS7
    CIS
    thioredoxin MOL 294
    superoxide dismutase (SOD) SOD1 (soluble, CuZn) triethylenetetramine (TETA) 
    KCN
    SOD2 (mitochondrial, Mn)
    SOD3 (in Mus musculus, extracellular, CuZn)
    Bcl-2 family antiapoptotic members(group I) : BH4-BH3-BH2-BH1 -TM (~ CED9 in Caenorhabditis elegans) pro-apoptotic members (~ egl-1 in Caenorhabditis elegans
    proteins containing His residues diethylpyrocarbonate
    proteins containing Cys residues iodoacetamide
    family (identity > 40%)
    subfamily (identity > 55%)
    isoform
    CYP1A1 (up-regulated by AHR) aromatic compounds
    CYP1A2 aromatic compounds
    flutamide
    CYP1B1 dioxin
    CYP2A phenobarbital
    CYP2A6 tegafur
    CYP2A7
    CYP2A13
    CYP2B
    CYP2B6 (up-regulated by VDR) cyclophosphamide orphenadrine 
    CYP2B7
    CYP2C (Rattus norvegicus) mephenytoin
    paclitaxel
    CYP2C8 mephenytoin
    CYP2C9 : 3 SNPs (up-regulated by VDR) mephenytoin
    warfarin
    phenytoin
    sulfonylureas
    CYP2C18 mephenytoin
    CYP2C19 : 8 SNPs mephenytoin
    PPIs
    CYP2D4 (in Mus musculus only)
    CYP2D5 (in Mus musculus only)
    CYP2D6 (in Homo sapiens only) (not inducible !) : ~ 70 SNPs 
    • poor metabolizers (PM)
    • intemediate metabolizers (IM)
    • extensive metabolizers (EM)
    • ultrarapid metabolizers (UM)
    ~ 65 drugs (most abandoned nowadays due to SNPs) : 
    debrisoquine 
    sparteine 
    codeine
    methadone
    tyramine 
    tryptamine 
    paroxetine
    fluoxetine
    tamoxifen
    quinidine
    SSRIs
    CYP2E1 (in both Homo sapiens and Mus musculus) ethanol
    acetaminophen => N-acetyl-p-benzoquinoneimine
    benzene
    phenol 
    chlorophorm
    lungs
    CYP2F1
    CYP2G1
    CYP2G2
    CYP2J2 arachidonic acid
    CYP2S1
    CYP3A niphedipine
    cyclosporine A
    tacrolimus
    troleandomycin
    CYP3A4 (up-regulated by VDR) 60% of clinically prescribed drugs :  enterocytes, hepatocytes, kidney troleandomycin
    CYP3A5 niphedipine
    CYP3A7 niphedipine
    CYP3A43
    CYP4A1 (Mus musculus)
    CYP4A3 (Mus musculus)
    CYP4A11
    CYP4B1
    CYP4F2 / LTB4 w-hydrolase  => 20-hydroxy-PGs
    CYP4F3 / LTB4 w-hydrolase  => 20-hydroxy-PGs
    CYP4F8  => 19R-hydroxyPGs
    CYP4F11
    CYP4F12
    CYP4X1
    CYP7A1 (rate-limiting enzyme in the neutral bile acid biosynthetic pathway)
    CYP7B1
    CYP8B1 / sterol 12a-hydroxylase
    CYP11A1 / cholesterol 20,22-desmolase / cholesterol side-chain-cleaving enzyme (P450scc) cholesterol aminoglutethimide (Cytadren©
    ketoconazole (Nizoral®) (at low doses)
    CYP11B1 / 11b-hydroxylase ketoconazole (Nizoral®
    metyrapone (Metopirone®)
    CYP11B2 / steroid 11b hydroxylase / 18-hydroxylase ketoconazole (Nizoral®)
    CYP17A1 / steroid 17a-hydroxylase / 17,20 lyase ketoconazole (Nizoral®) (at low doses) 
    CB7630 / abiraterone acetate
    CYP19 / aromatase androstenedione 
    testosterone
    16 a-hydroxyandrostenedione
    aromatase inhibitors (A) :
    • aminoglutethimide (Cytadren©, Orimeten®
    • dexaminoglutethimide 
    • YM-511 
    • MK0434
    • finrozole / MPV-2213ad (source : Hormos Medical Ltd., Turku, Finland) 
    • steroidal androstenedione analogs :
      • formestane (Lentaron®)
      • exemestane (Aromasin®)
    • imidazole or nonsteroidal structure (NSS)-AI :
      • anastrozole (Arimidex®)
      • fadrozole / CGS 16949 A (Afema®)
      • letrozole (Femara®; source : Novartis) : used in 13 cases as a fertility treatment because it suppresses estrogen and can promote ovulation, it is actually teratogenic and cause miscarriages and should be used only in postmenopausal women with breast cancer
      • vorozole
    CYP21A2 / steroid 21-hydroxylase
    CYP24 / steroid 24-hydroxylase (up-regulated by VDR)
  • 1a,25-(OH)2-vitamin D3 => 1a,24R,25-(OH)3-vitamin D3
  • 25-(OH)-vitamin D3 => 24R,25-(OH)2-vitamin D3
  • inner mitochondrial membrane of proximal convoluted renal tubule cells
    CYP26A1 all-trans retinoic acid
    CYP27A1 / steroid 25-hydroxylase vitamin D3=> 25-(OH)-vitamin D3 hepatocytes HIV-protease inhibitors
    CYP27B1 / steroid 1a-hydroxylase (down-regulated by VDR) 25-OH-vitamin D3 => 1a,25-(OH)2-vitamin D3 inner mitochondrial membrane of proximal convoluted renal tubule cells, activated macrophages, activated astrocytes, keratinocytes, placenta  HIV-protease inhibitors
    CYP39A1
    CYP46 / cholesterol 24-hydroxylase
    CYP51A1 / steroid 14a-demethylase ketoconazole (Nizoral®)
    NAT1
    NAT2 : 15 SNPs isoniazid
    procainamide
    dapsone
    hydralazine
    caffeine
    dihydropyrimidine dehydrogenase (DPYD) 5-FU
    thiopurine S-methyltransferase (TPMT) 6-MP
    epoxide hydrolase 1 valproic acid
    TGM1 / K polypeptide epidermal type I, protein-glutamine-g-glutamyltransferase
    TGM2 / C polypeptide, protein-glutamine-g-glutamyltransferase immunodominant gluten peptide in which Gln has been replaced with a 6-diazo-5-oxo-Nle residue
    TGM3 / E polypeptide, protein-glutamine-g-glutamyltransferase
    TGM3-like
    TGM4 prostate
    TGM5
    TGM6 / coagulation factor XIII
    TGM7 / transglutaminase Z
    aminopeptidase N / CD13 competitive inhibitors : 
    • ubenimex
    • actinonin
    methionine aminopeptidase-1 (MetAP-1)
    methionine aminopeptidase-2 (MetAP-2)
  • replacement of the C4 side chain by benzyloxime preserves the inhibitory activity against MetAP-2 enzyme
    • fumagillin
    • ovalicin
    • bestatin-type
      • A-357300
    • O-(chloracetyl-carbamoyl) fumagillol / TNP-470 /AGM-1470, an analogue of fumagillin toxic to proliferative endothelial cells : a water-soluble conjugate of biocompatible N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer, Gly-Phe-Leu-Gly linker and TNP-470 prevents it crossing the blood–brain barrier (BBB), and also leads to its selective accumulation in tumour vessels because of the enhanced permeability and retention (EPR) effect, thereby minimizing weight loss and neurotoxicityref

    • FK866/K22.175 (FK-866), developed as an anticancer agent, interferes with the NAD+ biosynthesis and  a strong antiangiogenic potencyref

     
    ATP-binding cassette (ABC) proteins : the human's 49 known ABC genes are beat out by fly, worm and mouse (56, 56, and 51 respectively), and are dwarfed by the 129 known Arabidopsis thaliana genes. ABCA1 (monomeric) liver, intestine, placenta, adipose, and spleen
    ABCA2
    ABCA3
    ABCA4
    ABCA5
    ABCA6
    ABCA7
    ABCA8
    ABCA9
    ABCA10
    ABCA11
    ABCA12
    ABCA13
    ABCB1/ P-glycoprotein (P-GP) / MDR1 / GP170
  • lumenal surface of brain capillaries (blood-brain barrier (BBB))
  • neurons
  • testes
  • proximal renal tubular cells
  • enterocytes
  • pancreas
  • bronchial mucosa
  • hepatocytes
  • placenta
  • low expression on blood cells, gonads, and breast
  • amphipathic, lipid soluble ::  first-generation agents : second-generation agents :
    • biricodar dictrate (Incel®)
    • valspodar / PSC 833 (Amdray®)
    third-generation inhibitors : 
    • laniquidar / R101933
    • ONT-093
    • tariquidar / XR9576
    • zosuquidar trihydrochloride / LY335979
     
    ABCB2 / TAP1
    ABCB3 / TAP2
    ABCB4
    ABCB5
    ABCB6 iron
    ABCB7 heme from mitochondria to cytosol
    ABCB8
    ABCB9
    ABCB10
    ABCB11 / bile salt efflux pump (BSEP) bile salts across hepatocyte canalicular mebrane into bile
    ABCC1 / MDR-associated protein type 1 (MRP1)
  • oxidized glutatione
  • cysteinyl leukotrienes
  • activated aflatoxin B1

  • glucuronides and sulfate conjugates of steroid hormones and bile salts
    ABCC2 / MDR-associated protein type 2 (MRP2)
  • brush border of proximal renal tubule
  • hepatocytes

  • apical membrane of enterocytes
    amphipathic anions and conjugated metabolites 
    • vinblastine
    • glucuronides
    • sulfates
    • glutathione adducts
    ABCC3 / MDR-associated protein 3 (MRP3)
    ABCC4 / MDR-associated protein 4 (MRP4) brain tumor cells topotecan
    ABCC5 / MDR-associated protein 5 (MRP5)
    ABCC6 / MDR-associated protein 6 (MRP6)
    ABCC7 / CFTR is unique among ABC proteins in that its transmembrane domains comprise an ion channel. Opening and closing of the pore have been linked to ATP binding and hydrolysis at CFTR's 2 nucleotide-binding domains, NBD1 and NBD2)ref Cl-
    HCO3- + Cl-
    2-thioxo-4-thiazolidinones : 
    • CFTRinh-172 (Ki = 300 nM)
    glyburide / glibenclamide (Micronase®, Diabeta®, Euglucan®, Glynase®; Glucovance® in combination with metformin
    niflumic acid (NFA) (Niflam®
    diphenylamine-2-carboxylate
    ABCC8 / MDR-associated protein 8 (MRP8) / sulfonylurea receptor 1 (SUR1) (associated to KCNJ11)ref b cells of pancreatic Langerhans' isletsref a endosulfine
    b endosulfine
    sulfonylureas :
    • first-generation analogs
      • tolbutamide (Orinase®)
      • chlorpropamide (Diabinese®; Chlorformin® in combination with phenformin)
      • tolazamide (Tolinase®)
      • acetohexamide (Dymelor®)
    • second-generation analogs
      • glyburide / glibenclamide (Micronase®, Diabeta®, Euglucan®, Glynase®; Glucovance® in combination with metformin)
      • glipizide (Glucotrol®)
      • gliclazide (Diamicron®, ...)
        • immediate release (IR)
        • modified reease (MR)
      • glimepiride (Amaryl®)
    meglitinide analogues : 
    • repaglinide (Prandin®
    • nateglinide (Starlix®)
    • mitiglinide / KAD-1229
    ABCC9 / sulfonylurea receptor 2 (SUR2)ref cardiac, skeletal, and vascular and non-vascular smooth muscle sulfonylureas: 
    • first-generation analogs
      • tolbutamide (Orinase®)
      • chlorpropamide (Diabinese®)
      • tolazamide (Tolinase®)
      • acetohexamide (Dymelor®)
    • second-generation analogs
      • glyburide / glibenclamide (Micronase®, Diabeta®, Glynase®; Glucovance® in combination with metformin)
      • glipizide (Glucotrol®)
      • gliclazide (Diamicron®, ...)
        • immediate release (IR)
        • modified reease (MR)
      • glimepiride (Amaryl®)
    meglitinide analogues 
    • repaglinide (Prandin®
    • nateglinide (Starlix®)
    • mitiglinide / KAD-1229
    ABCC10 / MDR-associated protein 7 (MRP7)
    ABCC11 / MDR-associated protein 8 (MRP8)
    ABCC12 / MDR-associated protein 9 (MRP9)
    ABCC13
    ABCD1
    ABCD2
    ABCD3
    ABCD4
    ABCE1
    ABCF1
    ABCF2
    ABCF3
    ABCG1 (dimeric) macrophages
    ABCG2 cancer cells  mitoxantrone (sequestered into extracellular vesiclesref) Ko143 
    fumitremorgin C
    ABCG3
    ABCG4 (dimeric) macrophages
    ABCG5 / sterolin-1 (dimeric) liver and small intestine (apical sterol export pumps that promote active efflux of cholesterol and plant sterols from enterocytes back into the intestinal lumen for excretion) sterolins / phytosterols
    ABCG8 / sterolin-2 (dimeric)
    ATP1A1 : ATPase, Na+/K+ transporting, alpha 1 polypeptide
    ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide
    ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide
    ATP1A4 ATPase, Na+/K+ transporting, alpha 4 polypeptide
    ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide
     ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide
     ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide
     ATP1B4 ATPase, (Na+)/K+ transporting, beta 4 polypeptide
    sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) ATP2A1 / SERCA1 cardiac muscle, fast twitch 1 thapsigargin
    L12ADT
    ATP2A2 / SERCA2 (2 isoforms : SERCA2a and SERCA2b)  cardiac muscle, slow twitch 2 thapsigargin
    L12ADT
    ATP2A3 / SERCA3 ubiquitous thapsigargin
    L12ADT
     ATP3 ATPase, Mg++ transporting
    ATP4A ATPase, H+/K+ exchanging, alpha polypeptide
    ATP4B ATPase, H+/K+ exchanging, beta polypeptide
    ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle
    ATP5A2 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 2, non-cardiac muscle
    ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide
    ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1
    ATP5C2 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 2
    ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit
    ATP5E ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit
    ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1
    ATP5G1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 
     ATP5G2 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 2
     ATP5G3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9) isoform 3
     ATP5H ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d
     ATP5I ATP synthase, H+ transporting, mitochondrial F0 complex, subunit e
     ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6
     ATP5L ATP synthase, H+ transporting, mitochondrial F0 complex, subunit g 
    MTATP6 ATP synthase 6 
    ATP7A ATPase, Cu+ transporting, a polypeptide (Menkes syndrome)
    ATP7B ATPase, Cu+ transporting, b polypeptide (Wilson disease)
    MTATP8 ATP synthase 8
    ATP9A ATPase, Class II, type 9A
    ATP9B ATPase, Class II, type 9B 
    ATP10A ATPase, Class V, type 10A 
    ATP10B ATPase, Class V, type 10B 
    ATP10D ATPase, Class V, type 10D 
    ATPAF1 ATP synthase mitochondrial F1 complex assembly factor 1 
    ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2
     
    farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase) bisphosphonates are pyrophosphate analogs :
    • first-generation, nonnitrogen-containing bisphosphonates have antiresorptive activity at dose levels from 0.1 to 10 mg P/kg. Some first generation analogues are now used to treat metabolic bone disease but, when given orally, their efficacy in aggressive resorptive disease may be limited because of low potency
      • clodronate (Bonefos®)
      • etidronate sodium / ethylenehydroxydiphosphonate (Didrocal®, Didronel®)
    • aminobisphosphonates / nitrogen-containing bisphosphonates (N-BPs)
      • second generation amino-bisphosphonates characterized by an amino terminal group and a higher antiresorptive potency (in growing rats ranges from 0.01 to 1 mg P/kg.)
        • alendronate (Fosamax®; Merck and Company, Inc.; West Point, PA) p.o.
        • pamidronate / aminohydroxypropane diphosphonate (Aredia®; Novartis Pharmaceuticals Corp.; East Hanover, NJ) i.v.
      • third generation bisphosphonates are characterized by a cyclic chain, was synthesized. It includes series of pyridinyl ethane bisphosphonates, pyridinyl aminomethane bisphosphonates, indan bisphosphonates, cyclopentane bisphosphonates, piperidyl ethane bisphosphonates, pyridinyl and piperidyl hydroxyethane bisphosphonates, piperidinylidene aminomethane bisphosphonates, and pyridinyl oxa- and thiomethane bisphosphonates. Several of these show antiresorptive activity in growing rats as low as 0.001 mg P/kg
        • ibandronate (Bondronat®, Bonvival®; Hoffmann-La Roche Inc.; Nutley, NJ) i.v.
        • risedronate (Actonel®; Actonel with Calcium® in combination with calcium carbonate; Proctor and Gamble Pharmaceuticals, Inc.; Cincinnati, OH) p.o.
        • zoledronate (Zometa®; Novartis Pharmaceuticals Corp.) i.v.
    • medronate / methylene diphosphonate
    • minodronate (YM529)
    • neridronate
    • olpadronate
    • oxidronate / hydroxymethylene diphosphonate
    • tiludronate (Skelid®)
    farnesyl-diphosphate farnesyltransferase 1 (FDFT1) farnesyl pyrophosphate  farnesyl transferase inhibitors (FTI) : synthetic FTIs have been designed based on the structures of 2 substrates that are involved in the reaction, FPP and Ras CAAX tetrapeptide. Ras-competitive inhibitors that have been synthesized, both CAAX-related and CAAX-unrelated, display nanomolar inhibitory potency toward FTase but retain selectivity against GGTase-I
    • p.o.
      • lonafarnib / SCH66336 (Sarasar®)

      • tipifarnib / R115777 (Zarnestra®)

    • i.v. : BMS-214662
    • J-104,871ref

    poly(ADP-ribose) polymerase (PARP) PJ34 (phenanthridinone-based)
    INO-1001 
    3-aminobenzamide (ABA)
    3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2h)-isoquinolinone
    thiamine pyrophosphokinase thiamine => TPP / TDP neopyrithiamine / pyrithiamine 
    oxythiamine
    pyridoxal kinase pyridoxal => pyridoxal phosphate isonicotinic acid hydrazone
    calmodulins calmodulin 1
    calmodulin 2
    calmodulin 3
    calmodulin-like 1
    calmodulin-like 3
    zaldaride
    glyceraldehyde-3-phosphate dehydrogenase (GAPDH) koningic acid (KA)
    telomerase reverse transcriptase (TERT) catalytic inhibitors 
    antisense phosphorothioate (AS-ONS) for telomerase template
    • GRN163 (a 13-mer N3'-->P5' thio-phosphoramidate (NPS) oligonucleotide)
    folding of the DNA substrate 
    inhibitors of the HSP90 chaperone function :
    • geldanamycin (GA)
    • 17-allylamino,17-demethoxygeldanamycin (17-AAG)
    AZT / zidovudine
    lamivudine
    3-(3,5-dichlorophenoxy)-nitrostyrene (DPNS) 
    2,3,7-trichloro-5-nitroquinoxaline (TNQX) 
    dictyodendrins A-E (1-5) 
    2,3-dibromosuccinato [2-(methylaminomethyl)pyridine]platinum (II) (compound E) 
    epigallocatechin gallate (EGCG) and synthetic derivatives : 
    • SR13193
    • SR13196
    gossypol
    MST-312 
    MST-295 
    MST-1991
    arabinofuranosylguanine 5'-triphosphate (araGTP) 
    3'-azido-2',3'-dideoxyguanosine 5'-triphosphate (AZdGTP) 
    2',3'-dideoxy-2'-fluoroarabino-furanosylguanine 5'-triphosphate (FaraGTP) 
    quadruplex telomeric G-rich ssDNA
    • telomestatin (SOT-095)
    matrix metalloproteinases (MMP) : multidomain zinc endopeptidases with a metzincin-like catalytic domain MMP1 / interstitial collagenase batimastat / BB-94 (hydroxamate peptidomimetic ) 
    ilomastat / galardin / GM 6001 
    marimastat / BB 2516 / TA 2516 (orally bioavailable analogue )
    SC 44463 
    o-phenanthroline 
    collagen peptidomimetics 
    nonpeptidomimetic inhibitors of the MMP active site
    tetracycline derivatives competing for Zn :  bisphosphonates
    MMP2 / gelatinase A / 72 kDa type IV collagenase
    MMP3 / stromelysin 1 / progelatinase
    MMP7 / uterine matrilysin
    MMP8 / neutrophil collagenase
    MMP9 / gelatinase B / 92 kDa type IV collagenase
    MMP10 / stromelysin 2
    MMP11 / stromelysin 3
    MMP12 / macrophage elastase
    MMP13 / collagenase 3
    MMP14 / MT1-MMP / membrane inserted (an activator of MMP-2)
    MMP15 / membrane inserted
    MMP16 / membrane inserted
    MMP17 / membrane inserted
    MMP18 / MMP19
    MMP20 / enamelysin
    MMP21
    MMP23A
    MMP23B / MMP22
    MMP24 / membrane inserted
    MMP25
    MMP26
    MMP27
    MMP28
    calpain MDL 28170 
    cholesteryl ester transfer protein, plasma (CETP) hepatocytes JTT-705 
    torcetrapib / CP-529414 
    lipase, gastric orlistat / tetrahydrolipstatin (THL) (Xenical®)
    ATL-962
    lipase, pancreatic orlistat / tetrahydrolipstatin (THL) (Xenical®
    ATL-962
    HMG-CoA reductase HMG-CoA hepatocytes -statins / HMGRIs  : 
    • atorvastatin (Lipitor®, Totalip®)
    • cerivastatin (Baycol®, Stativa®, Cervasta®)
    • fluvastatin (Lescol®)
    • lovastatin / mevilonin (prodrug) (Mevacor®)
    • mevastatin / compactinref
    • pitavastatin / NK-104 (Livalo®)
    • pravastatin (Pravachol®)
    • rosuvastatin / ZD4522 (Crestor®, Simestat®)
    • simvastatin (prodrug) (Zocor®; Inegy® in combination with ezetimibe)
    microsomal triglyceride transfer protein (MTP) BMS-201038
    acylCoA:cholesterol acyltransferase 1 (ACAT-1) cholesterol, acylCoA macrophage avasimibe / CI-1011
    acylCoA:cholesterol acyltransferase 2 (ACAT-2) cholesterol enterocytes and hepatocytes
    lipoprotein lipase (LPL) adipocytes, skeletal muscle cells, and macrophages (including foamy cells in atherosclerotic lesions, where it can bind and retain LDLs in subendothelial space)
    hepatic triglyceride lipase (HTGL) hepatocytes
    phospholipid transfer protein (PLTP) liver and lungs
    lecithin:cholesterol acyl transferase (LCAT) hepatocytes
    squalene synthase / farnesyl-diphosphate farnesyl transferase 1 farnesyl pyrophosphate  squalestatin 1ref
    zaragosic acids A, B, and C (fungal metabolites)ref
    1,1-bisphosphonate esters :
    • SR-45023A (ApomineTM) ?ref

    • SR-12813ref
    ER-27856  5-{N-[2-butenyl-3-(2-methoxyphenyl)]-N-methylamino}-1,1-penthylidenebis(phosphonic acid) trisodium saltref

    RPR 107393 {3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo[2-2-2]octane dihydrochloride} and its R and S enantiomers (p.o.; also inducer of HMG-CoA reductase, resulting in the accumulation of metabolites of FPP. After the administration of radiolabeled mevalonate, hepatic levels of labeled dicarboxylic acids in RPR 107393-treated rats were shown in the present study, raising the possibility of toxicity with this treatment. It is known, however, that dicarboxylic acids derived from geraniol are readily excreted in urine, so rapid urinary excretion as the dicarboxylic acids may be the fate of the accumulated mevalonate after RPR 107393 treatmentref)
    some bisphosphonatesref1, ref2
    GTP cyclohydrolase I (GTPCH) 2,4-diamino-6-hydroxypyrimidine
    N-acetyl-L-aspartyl-L-glutamate (NAAG) peptidase / glutamate carboxypeptidase II (GCPII) N-acetyl-aspartyl-glutamate (NAAG) 2-(phosphonomethyl) pentanedioic acid (2-PMPA) 
    ZJ-43
    GTP-binding proteins, or GTPasesref, are proteins that cycle back and forth between 2 conformations that determine their activity: in the first conformation, they are bound by a GTP cofactor that activates them biochemically; whereas, in the second conformation, they are GDP-bound and inactive. GTPases have hydrolysis activity that catalyses the conversion of the GTP moiety to GDP or GMP (GDP in the case of the p47 GTPases). The level of hydrolysis activity varies for particular GTPases, and it canbe modulated by other cellular factors, such as GTPase-activating factors, such as GTPase-activting proteins (GAPs). Once the protein is in the GDP-bound/inactive state, a cellular guanine exchange factor (GEF) catalyses the replacement of GDP with GTP, which reactivates the protein. So, the activity of GTPases is regulted by functions that are inherent to the protein as well as by accessory proteins. The fraction of the GTPase that is in the active state varies widely according to the particular GTPase, and according to the cellular environment. For example, the small GTPase RAS is about 7% GTP-bound in queiescent fibroblasts, but becomes more active and 22% is GTP-bound in fibroblasts that have been transformed by the v-src and v-abl virusesref. By contrast, most of the p47 GTPases in cells seem to be in a GTP-bound state, and are therefore active. At the primary sequence level, GTPases have 3 conserved amino-acid motifs- Gly-Xaa-Xaa-Xaa-Xaa-Gly-Lys(Ser/Thr), Asp-Xaa-Xaa-Gly and Asn-Lys-Xaa-Asp - that bind the guanine nucleotide and a Mg2+ cofactorref. In addition, some GTPases are membrane bound, with a covalently attached lipid chain such as myristoyl or prenyl group that medites association with the membraneref. Once in the GTP-bound state, GTPases effect their functions, which range from activation of cell surface receptors to modulation of membrane-fusion events. Although the precise cellular function of the p47 GTPases is unknown, GTP binding triggers the formation of oligomeric complexes.

    Copyright © 2001-2005 Daniele Focosi. All rights reserved Terms of use  | Legal notices
    About this site  |  Site map  |  Acknowledgements | Open forum  |  Tell a friend about this site  |  Current link partners
     Abbreviations and acronyms  |  Medical terminology  |  Add a link  |  Translate this site into your favourite language  |  Softwares


    This website subscribes to the HONcode principles of the HON Foundation. Click to verify.
    PicoSearch
     

    Search 
    Search 
    for 
    Search Medical Dictionary
    for